Novel Laser Therapy Offers Hope for Macular Degeneration Patients in Bari
Bari, Italy – A new treatment offering a potential lifeline to patients suffering from chronic central serous chorioretinopathy (CSCR) and other vascular retinal diseases is now available at the Ospedale Di Venere. The therapy, known as photodynamic therapy (PDT), utilizes a targeted laser to “dry” the macula, the central part of the retina responsible for sharp, detailed vision, and preserve sight. This advancement marks a significant step forward in specialized eye care within the Puglia region, reducing the necessitate for patients to seek treatment elsewhere.
The macula can become compromised by an accumulation of fluid beneath the retina, a condition known as CSCR. This fluid buildup disrupts the delivery of oxygen and nutrients to the photoreceptors, potentially leading to irreversible vision loss if left untreated. CSCR often affects young to middle-aged adults, particularly men, and can be exacerbated by chronic stress and corticosteroid use. The introduction of PDT at the Di Venere hospital provides a crucial treatment option for those grappling with this debilitating condition, offering a chance to stabilize vision and prevent further deterioration.
Understanding Photodynamic Therapy
Photodynamic therapy is a minimally invasive procedure that involves two key steps. First, a photosensitizing substance is administered intravenously. This substance is absorbed by the abnormal blood vessels in the retina. Subsequently, a non-thermal laser is applied to the macula, activating the photosensitizer and selectively targeting the leaky blood vessels responsible for the fluid buildup. The goal is to reduce fluid accumulation and stabilize visual function. According to experts, PDT is now considered the “gold standard” for treating chronic forms of CSCR.
A Regional Benefit and Experienced Team
The Oculistica department at the Di Venere hospital, under the direction of Dr. Antonio Acquaviva, has spearheaded the implementation of this new therapy. Dr. Claudio Furino, with over 300 PDT treatments already performed, played a key role in establishing the procedure at the hospital. The availability of PDT at the Di Venere is particularly significant as it was previously limited to only a few centers within the Puglia region. This expansion of access means patients can now receive specialized care locally, minimizing the need for “migrazione sanitaria” – traveling to other regions for treatment – and its associated burdens.
What is Central Serous Chorioretinopathy?
Central serous chorioretinopathy (CSCR) is a condition that affects the macula, the central part of the retina responsible for sharp, detailed vision. It’s characterized by the accumulation of fluid beneath the retina, causing it to become detached and distorted. This fluid buildup disrupts the normal functioning of the photoreceptor cells, leading to blurred or distorted vision, and potentially, permanent vision loss. While the exact cause of CSCR is often unknown, risk factors include stress, corticosteroid use, and certain personality traits. The condition typically affects individuals between the ages of 25 and 55, with a significantly higher prevalence among men.
The Procedure and What to Expect
The PDT procedure itself is relatively quick and minimally invasive. Patients receive an intravenous infusion of a photosensitizing drug, which selectively accumulates in the abnormal blood vessels. After a waiting period to allow for adequate drug absorption, a non-thermal laser is precisely directed at the affected area of the macula. The laser activates the photosensitizer, causing damage to the leaky blood vessels and reducing fluid leakage. The procedure aims to stabilize vision and prevent further deterioration, offering patients a chance to maintain their quality of life. The therapy is also used in the treatment of severe vascular choroidal pathologies.
Looking Ahead
The introduction of PDT at the Ospedale Di Venere represents a significant investment in advanced ophthalmic care for the Puglia region. By providing access to this cutting-edge treatment, the hospital is empowering patients to preserve their vision and maintain their independence. The team at the Oculistica department continues to monitor advancements in retinal therapies and is committed to offering the best possible care to their patients. Further updates on the program’s progress and patient outcomes are expected in the coming months.
The hospital is committed to expanding its capabilities in treating complex retinal conditions, ensuring that residents of Bari and the surrounding areas have access to world-class eye care. The success of this program will likely pave the way for the introduction of other innovative therapies in the future.
Have you or a loved one been affected by macular degeneration or CSCR? Share your experiences and thoughts in the comments below. Please also share this article with anyone who might benefit from this information.